IGC Pharma price to sales ratio IGC

Market value divided by revenue over the last twelve months, since 2012.

Today, Oct 23, 2026: 22.6×
10-year median: 20.9×
Against its 10-year history: 56th; percentile: 0 is its lowest day, 100 its highest
10-year range: 1.6× to 195×
Peer median: 0.4×

IGC Pharma's price to sales ratio is 22.6× as of Oct 23, 2026.

That is above its ten-year median of 20.9×, close to the middle of its last ten years.

Over that time it ranged from 1.6× in Nov 2016 to 195× in Aug 2021.

The median for 4 large drugmakers of a similar size is 0.4×.

Price to sales ratio over time

median 20.9×

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	22.6×	21.0×	28.5×
2025	25.2×	17.4×	29.7×
2024	24.2×	12.6×	34.0×
2023	13.3×	12.5×	32.5×
2022	24.9×	24.9×	163×
2021	155×	48.2×	195×
2020	49.1×	2.5×	62.7×
2019	3.9×	2.5×	18.4×
2018	2.3×	2.3×	55.3×
2017	44.4×	2.5×	44.4×
2016	2.7×	1.6×	3.2×
2015	n/m a value too high to mean anything
2014	2.6×	0.8×	3.7×
2013	1.0×	0.8×	2.1×
2012	1.6×	1.6×	3.3×

Against its peers

Companies in Drug Manufacturers - General nearest IGC Pharma's size, closest first, today.

Company	Price to sales ratio
IGCIGC Pharma	22.6×
ATNMActinium Pharmaceuticals	n/m
SPROSpero Therapeutics	1.4×
LFVNLifevantage	0.4×
NATRNatures Sunshine Products	0.4×
Peer median	0.4×

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on IGC Pharma

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.